BERLIN — The European Society for Medical Oncology (ESMO) has just dropped its first-ever guidelines on how oncologists should use large language models (LLMs), a cutting-edge AI tech, in cancer treatment. The guidance, published in the Annals of Oncology, comes as the ESMO annual meeting kicks off in Berlin.
ESMO experts are clear: AI’s potential to transform cancer care is immense, but they’re also sounding the alarm on the lack of thorough evaluations and safety tools for these chatbots. While the American Society of Clinical Oncology (ASCO) has its own AI principles, ESMO’s new guidance is the first to focus specifically on LLMs.
So, what’s the buzz about LLMs? These AI models can generate human-like text, offering exciting possibilities in cancer care, like improving patient-doctor communication or aiding in medical research. But, as with any new tech, there are risks. ESMO’s guidance is a wake-up call for oncologists to tread carefully and ensure patient safety.
Want to dive deeper into this AI revolution in cancer care? Keep reading on STAT+!
